NanoViricides is making significant strides in developing a potential antiviral treatment for Measles and MPox as global case numbers surge and existing vaccines show limitations. The company's lead drug candidate, NV-387, is positioning itself to address critical gaps in viral treatment options.
The pharmaceutical development-stage company has initiated key steps toward advancing NV-387's potential deployment. For Measles, the company has begun preparations for animal efficacy studies and will make the drug available through the FDA's Individual Patient Expanded Access program. In the Democratic Republic of the Congo, the company has secured clearance from the national ethics committee for its Phase II Clinical Trial Application for MPox.
Currently, no approved drugs exist specifically targeting Measles or MPox, making NanoViricides' research potentially transformative for global public health. Beyond these specific viral targets, NV-387 is also being developed for broader applications, including treatment of respiratory infections and pan-herpesvirus applications.
The strategic development of NV-387 represents a significant potential advancement in antiviral therapeutics, particularly as infectious diseases continue to pose substantial global health challenges. By focusing on creating specialized nanomaterials for antiviral therapy, NanoViricides is addressing critical unmet medical needs in viral treatment.
